We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Creative Medical Technology Holdings Inc (CELZ) USD0.0001

Sell:$1.69 Buy:$1.71 Change: $0.002 (0.12%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.002 (0.12%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.002 (0.12%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company. The Company is focused on immunology, urology, neurology, and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. The Company conducts its commercial operations through its subsidiary, Creative Medical Technologies, Inc. (CMT). CMT markets and sells its CaverStem and FemCelz disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction (ED) and female sexual dysfunction, respectively. Its products include CaverStem, FemCelz, StemSpine, ImmCelz and OvaStem. StemSpine is a regenerative stem cell procedure for the treatment of degenerative disc disease. ImmCelz is a universal donor stem cell therapy for stroke treatment. OvaStem is a stem cell therapy for premature ovarian failure. It is also focused on the use of its technologies covering treatments for various diseases.

Contact details

211 E. Osborn Rd.
United States
+1 (480) 3992822

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$12.05 million
Shares in issue:
6.51 million
United States
US dollar

Key personnel

  • Timothy Warbington
    President, Chief Executive Officer, Director
  • Donald Dickerson
    Chief Financial Officer, Senior Vice President, Director
  • Sahil Nock
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.